Maheen Sheraz
Research Subjects
Maheen Sheraz has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Umer Sajid
Rashid Latif Medical College, Lahore, Pakistan
7 shared publications - Umama Alam
Khyber Medical College Peshawar Pakistan
3 shared publications - Allahdad Khan
Department of Medicine, Nishtar Medical University, Multan, Pakistan
2 shared publications - Minahil Zaheer
HBS Medical and Dental College, Islamabad, Pakistan
2 shared publications - Muhammad Abdullah Ali
Khyber Medical College Peshawar Pakistan
2 shared publications - Muneeba Umar
HBS Medical and Dental College, Islamabad, Pakistan
2 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e51057
Kartagener syndrome with pulmonary mycetoma and recurrent thromboembolism
Rationale: Kartagener syndrome, a variant of primary ciliary dyskinesia, is defined by chronic sinusitis, bronchiectasis, and situs inversus. While recurrent infections are seen, a combination of thromboembolic disease, pulmonary mycetoma, cardiac dysfunction, and serological evidence of autoimmune disorders is very uncommon. Patient concerns: A 27-year-old man with Kartagener syndrome and situs inversus totalis complaining of worsening dyspnea, chest pain, fever, hemoptysis, and ankle swelling. His past medical history included episodes of deep vein thrombosis, recurrent pulmonary embolism, and chronic productive cough. Diagnoses: Radiologic studies showed dextrocardia, a right upper lobe cavitary lesion indicative of pulmonary mycetoma, hepatic congestion, and ascites. The echocardiogram demonstrated severe dysfunction of both left and right ventricles, a thrombus in the right ventricle, mild-moderate pericardial effusion, and an ejection fraction of about 40%. BNP was elevated, and U1-ribonucleoprotein antibodies were positive, implying a probable overlap of autoimmune disease, but diagnostic criteria were not fulfilled. Interventions: He was prescribed appropriate heart failure management, anticoagulant therapy, antifungals, and multidisciplinary treatment of other issues. Outcomes and Lessons: The patient underwent adequate management of his cardiopulmonary, infectious, and thromboembolic complications. The existence of a causal link between these diseases could not be found. This case underscores the need for a multidisciplinary approach in evaluating patients with a combination of congenital and acquired systemic diseases. The association of Kartagener syndrome, pulmonary mycetoma, thromboembolic tendency, right ventricular thrombus formation, cardiac dysfunction, and positive U1-RNP is an unusual combination and calls for proper evaluation.
- 9 October 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (41) , e51057
Open AccessKartagener syndrome with pulmonary mycetoma and recurrent thromboembolism
Rationale: Kartagener syndrome, a variant of primary ciliary dyskinesia, is defined by chronic sinusitis, bronchiectasis, and situs inversus. While recurrent infections are seen, a combination of thromboembolic disease, pulmonary mycetoma, cardiac dysfunction, and serological evidence of autoimmune disorders is very uncommon. Patient concerns: A 27-year-old man with Kartagener syndrome and situs inversus totalis complaining of worsening dyspnea, chest pain, fever, hemoptysis, and ankle swelling. His past medical history included episodes of deep vein thrombosis, recurrent pulmonary embolism, and chronic productive cough. Diagnoses: Radiologic studies showed dextrocardia, a right upper lobe cavitary lesion indicative of pulmonary mycetoma, hepatic congestion, and ascites. The echocardiogram demonstrated severe dysfunction of both left and right ventricles, a thrombus in the right ventricle, mild-moderate pericardial effusion, and an ejection fraction of about 40%. BNP was elevated, and U1-ribonucleoprotein antibodies were positive, implying a probable overlap of autoimmune disease, but diagnostic criteria were not fulfilled. Interventions: He was prescribed appropriate heart failure management, anticoagulant therapy, antifungals, and multidisciplinary treatment of other issues. Outcomes and Lessons: The patient underwent adequate management of his cardiopulmonary, infectious, and thromboembolic complications. The existence of a causal link between these diseases could not be found. This case underscores the need for a multidisciplinary approach in evaluating patients with a combination of congenital and acquired systemic diseases. The association of Kartagener syndrome, pulmonary mycetoma, thromboembolic tendency, right ventricular thrombus formation, cardiac dysfunction, and positive U1-RNP is an unusual combination and calls for proper evaluation.
- Open Access
- 30 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5195-5203
Disparity trends in coexisting renal failure- and pulmonary hypertension-related mortality in the United States (1999–2020): CDC WONDER database study
Renal failure (RF) and pulmonary hypertension (PH) are major contributors to mortality in the United States (U.S.). Globally, RF affects around 11–13% of the population and is the 10th leading cause of death. In the U.S., 15% of adults are estimated to have CKD, with almost 90% undiagnosed. PH affects about 1% of the global population, rising significantly in older adults. RF and PH frequently coexist, especially in end-stage renal disease, amplifying mortality risk. We analyzed annual death certificate data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (1999–2020), identifying deaths with the International Statistical Classification of Diseases and Related Health Problems – 10th Revision codes N17–N19 (RF) and I27.x (PH). We calculated crude and age-adjusted mortality rates (AAMRs) per 100 000 and assessed temporal trends using Joinpoint regression. Analyses were stratified by sex, race/ethnicity, geographic region, and urban–rural status. Between 1999 and 2020, 63 394 deaths were attributed to combined RF–PH. Overall, AAMR rose from 7.17 to 18.11 per 100 000, with two joinpoints: a sharp rise until ~2012 [annual percentage change (APC) ~+5.8%], a dip through ~2015 (–6.7%), then a rebound (APC ~+5.9%). Increases were observed across sexes, races, regions, and urbanization, but were most pronounced among Black individuals (AAMR 14.07 → 31.29), rural populations, and Western states. From 1999 to 2020, RF- and PH-related mortality in the U.S. nearly tripled, with persistent disparities by race, geography, and urbanization. These findings highlight the need for targeted screening and interventions, especially in high-burden communities, to mitigate risk in vulnerable groups.
- 30 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (8) , 5195-5203
Open AccessDisparity trends in coexisting renal failure- and pulmonary hypertension-related mortality in the United States (1999–2020): CDC WONDER database study
Renal failure (RF) and pulmonary hypertension (PH) are major contributors to mortality in the United States (U.S.). Globally, RF affects around 11–13% of the population and is the 10th leading cause of death. In the U.S., 15% of adults are estimated to have CKD, with almost 90% undiagnosed. PH affects about 1% of the global population, rising significantly in older adults. RF and PH frequently coexist, especially in end-stage renal disease, amplifying mortality risk. We analyzed annual death certificate data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (1999–2020), identifying deaths with the International Statistical Classification of Diseases and Related Health Problems – 10th Revision codes N17–N19 (RF) and I27.x (PH). We calculated crude and age-adjusted mortality rates (AAMRs) per 100 000 and assessed temporal trends using Joinpoint regression. Analyses were stratified by sex, race/ethnicity, geographic region, and urban–rural status. Between 1999 and 2020, 63 394 deaths were attributed to combined RF–PH. Overall, AAMR rose from 7.17 to 18.11 per 100 000, with two joinpoints: a sharp rise until ~2012 [annual percentage change (APC) ~+5.8%], a dip through ~2015 (–6.7%), then a rebound (APC ~+5.9%). Increases were observed across sexes, races, regions, and urbanization, but were most pronounced among Black individuals (AAMR 14.07 → 31.29), rural populations, and Western states. From 1999 to 2020, RF- and PH-related mortality in the U.S. nearly tripled, with persistent disparities by race, geography, and urbanization. These findings highlight the need for targeted screening and interventions, especially in high-burden communities, to mitigate risk in vulnerable groups.
- Open Access
- 10 May 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (5)
Coexisting Hepatic and Renal Dysfunction During Pulmonary Tuberculosis Treatment: A Case Report
Anti‐tuberculosis therapy may rarely cause concurrent liver and kidney injury, with ANCA positivity suggesting immune involvement. This case highlights the importance of early recognition, treatment modification, and multidisciplinary care to prevent complications and ensure effective tuberculosis management.
- 10 May 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (5)
Open AccessCoexisting Hepatic and Renal Dysfunction During Pulmonary Tuberculosis Treatment: A Case Report
Anti‐tuberculosis therapy may rarely cause concurrent liver and kidney injury, with ANCA positivity suggesting immune involvement. This case highlights the importance of early recognition, treatment modification, and multidisciplinary care to prevent complications and ensure effective tuberculosis management.
- Open Access
- 27 March 2026
- Published by S. Karger AG in Endocrinology Insights
- p. 1-10
Cardiovascular Disease Mortality in Patients with Hypothyroidism: A 22-Year National Analysis of US Trends and Disparities
Introduction: Hypothyroidism is a prevalent endocrine disorder that has been linked to adverse cardiovascular outcomes. However, national-level trends and disparities in cardiovascular disease (CVD)-related mortality among individuals with hypothyroidism remain incompletely characterized. This study aimed to evaluate long-term temporal trends and demographic disparities in CVD mortality among US adults with hypothyroidism. Methods: We conducted a retrospective population-based analysis using death certificate data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2020. Adults aged ≥25 years with hypothyroidism were identified using ICD-10 codes E02–E03, with CVD-related deaths defined by ICD-10 codes I00–I99. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 US standard population. Temporal trends were analyzed using joinpoint regression to estimate annual percent change (APC), and subgroup analyses were performed by sex, race/ethnicity, age group, urban-rural status, and place of death. Results: Between 1999 and 2020, 382,906 CVD-related deaths were associated with hypothyroidism, corresponding to an overall AAMR of 8.00 per 100,000. Mortality rates increased steadily over the study period, peaking at 10.12 per 100,000 in 2020, with the most pronounced rise occurring between 2018 and 2020 (APC 14.01%). Women accounted for nearly three times as many deaths as men, although mortality rates increased more rapidly among men. Non-Hispanic white individuals exhibited the highest absolute mortality burden, while Hispanic populations experienced the fastest growth in mortality rates. The largest relative increases were observed among adults aged 35–44 and 45–54 years. Mortality rates were consistently higher in rural compared with urban areas, and the majority of deaths occurred in long-term care facilities. Conclusion: CVD-related mortality among US adults with hypothyroidism has risen substantially over the past two decades, with marked disparities across sex, age, race/ethnicity, and geographic location. These findings highlight the need for targeted cardiovascular risk assessment, early detection of hypothyroidism, and integrated management strategies, particularly in high-risk and underserved populations, to mitigate rising mortality and reduce health inequities.
- 27 March 2026
- Published by S. Karger AG in Endocrinology Insights
- p. 1-10
Open AccessCardiovascular Disease Mortality in Patients with Hypothyroidism: A 22-Year National Analysis of US Trends and Disparities
Introduction: Hypothyroidism is a prevalent endocrine disorder that has been linked to adverse cardiovascular outcomes. However, national-level trends and disparities in cardiovascular disease (CVD)-related mortality among individuals with hypothyroidism remain incompletely characterized. This study aimed to evaluate long-term temporal trends and demographic disparities in CVD mortality among US adults with hypothyroidism. Methods: We conducted a retrospective population-based analysis using death certificate data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2020. Adults aged ≥25 years with hypothyroidism were identified using ICD-10 codes E02–E03, with CVD-related deaths defined by ICD-10 codes I00–I99. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated using the 2000 US standard population. Temporal trends were analyzed using joinpoint regression to estimate annual percent change (APC), and subgroup analyses were performed by sex, race/ethnicity, age group, urban-rural status, and place of death. Results: Between 1999 and 2020, 382,906 CVD-related deaths were associated with hypothyroidism, corresponding to an overall AAMR of 8.00 per 100,000. Mortality rates increased steadily over the study period, peaking at 10.12 per 100,000 in 2020, with the most pronounced rise occurring between 2018 and 2020 (APC 14.01%). Women accounted for nearly three times as many deaths as men, although mortality rates increased more rapidly among men. Non-Hispanic white individuals exhibited the highest absolute mortality burden, while Hispanic populations experienced the fastest growth in mortality rates. The largest relative increases were observed among adults aged 35–44 and 45–54 years. Mortality rates were consistently higher in rural compared with urban areas, and the majority of deaths occurred in long-term care facilities. Conclusion: CVD-related mortality among US adults with hypothyroidism has risen substantially over the past two decades, with marked disparities across sex, age, race/ethnicity, and geographic location. These findings highlight the need for targeted cardiovascular risk assessment, early detection of hypothyroidism, and integrated management strategies, particularly in high-risk and underserved populations, to mitigate rising mortality and reduce health inequities.
- Open Access
- 19 March 2026
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 16 (1)
National Mortality Trends, Disparities, and Forecasted Burden of Atrial Fibrillation and Heart Failure with Underlying Ischemic Heart Disease Among Older Adults in the United States, 1999–2023
Background: Atrial fibrillation (AF) and congestive heart failure (CHF) remain major contributors to cardiovascular mortality in the United States. When accompanied by underlying ischemic heart disease (IHD), mortality risk is amplified. Although IHD mortality declined in the early 2000s, recent data suggest a resurgence. Methods: This population-based study used the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2023. Deaths were identified using ICD-10 codes I48 (AF) and I50.0 (CHF) as multiple causes of death and I20–I25 (IHD) as the underlying cause. Adults aged ≥ 65 years were included. Crude mortality rates (CMRs) and age-adjusted mortality rates (AAMRs) were calculated. Temporal trends were analyzed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Future mortality trends were projected using autoregressive integrated moving average (ARIMA) model. Results: From 1999 to 2023, AF, CHF, and IHD accounted for 219,188 deaths among adults ≥ 65 years. The overall AAMR increased from 193.8 per million in 1999 to 220.1 per million in 2023, with a decline from 1999 to 2010 followed by a sustained rise. Males (108,732 deaths) showed the steepest increase (AAPC + 1.40%, p < 0.001), whereas females (110,456 deaths) experienced a modest decline (AAPC − 0.55%, p < 0.001). Non-Hispanic Black adults had the largest racial increase (AAPC + 1.21%, p < 0.001). Non-metropolitan areas showed the greatest geographic rise (AAPC + 1.67%, p < 0.001). Conclusion: Mortality involving AF and CHF with underlying IHD among U.S. adults ≥ 65 years declined only temporarily before reversing after 2010. Persistent racial and geographic disparities underscore gaps in prevention and acute cardiovascular care. Clinical Trial Registration: Not applicable.
- 19 March 2026
- Published by Springer Nature in Journal of Epidemiology and Global Health
- Vol. 16 (1)
Open AccessNational Mortality Trends, Disparities, and Forecasted Burden of Atrial Fibrillation and Heart Failure with Underlying Ischemic Heart Disease Among Older Adults in the United States, 1999–2023
Background: Atrial fibrillation (AF) and congestive heart failure (CHF) remain major contributors to cardiovascular mortality in the United States. When accompanied by underlying ischemic heart disease (IHD), mortality risk is amplified. Although IHD mortality declined in the early 2000s, recent data suggest a resurgence. Methods: This population-based study used the CDC Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database from 1999 to 2023. Deaths were identified using ICD-10 codes I48 (AF) and I50.0 (CHF) as multiple causes of death and I20–I25 (IHD) as the underlying cause. Adults aged ≥ 65 years were included. Crude mortality rates (CMRs) and age-adjusted mortality rates (AAMRs) were calculated. Temporal trends were analyzed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Future mortality trends were projected using autoregressive integrated moving average (ARIMA) model. Results: From 1999 to 2023, AF, CHF, and IHD accounted for 219,188 deaths among adults ≥ 65 years. The overall AAMR increased from 193.8 per million in 1999 to 220.1 per million in 2023, with a decline from 1999 to 2010 followed by a sustained rise. Males (108,732 deaths) showed the steepest increase (AAPC + 1.40%, p < 0.001), whereas females (110,456 deaths) experienced a modest decline (AAPC − 0.55%, p < 0.001). Non-Hispanic Black adults had the largest racial increase (AAPC + 1.21%, p < 0.001). Non-metropolitan areas showed the greatest geographic rise (AAPC + 1.67%, p < 0.001). Conclusion: Mortality involving AF and CHF with underlying IHD among U.S. adults ≥ 65 years declined only temporarily before reversing after 2010. Persistent racial and geographic disparities underscore gaps in prevention and acute cardiovascular care. Clinical Trial Registration: Not applicable.
- 12 September 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2504
Liver transplantation in people living with HIV – methodological considerations and future directions
- 12 September 2025
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (12) , 2504
Liver transplantation in people living with HIV – methodological considerations and future directions
- Open Access
- 5 September 2025
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (2) , 1355-1356
Letter to the Editor: Comment on “Gastrointestinal Management Enhanced Recovery After Surgery Protocol Improves Postoperative Recovery in Patients Undergoing Posterior Lumbar Interbody Fusion”
- 5 September 2025
- Published by SAGE Publications in Global Spine Journal
- Vol. 16 (2) , 1355-1356
Open AccessLetter to the Editor: Comment on “Gastrointestinal Management Enhanced Recovery After Surgery Protocol Improves Postoperative Recovery in Patients Undergoing Posterior Lumbar Interbody Fusion”
- Open Access
- 1 September 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (9) , e70791
Efficacy and Safety of Tenecteplase in Acute Ischemic Stroke: A Meta‐Analysis of Randomized Controlled Trials
Introduction: Acute ischemic stroke (AIS) is the most common type of stroke, with increasing incidence and significant healthcare costs. Tenecteplase (TNK), a modified variant of tissue plasminogen activator (tPA), offers advantages such as a longer half‐life and single‐bolus administration. This meta‐analysis evaluates the safety and efficacy of TNK compared to non‐thrombolytic management in AIS to guide clinical decision‐making. Methodology: A comprehensive literature search across major databases identified randomized controlled trials (RCTs) comparing tenecteplase with non‐thrombolytic care in ischemic stroke. Data extraction and bias assessment were conducted independently, using RoB 2.0 and the GRADE framework. Meta‐analysis was performed using RevMan 5.4.1, applying random‐effects models and assessing heterogeneity with the I 2 statistic. Results: This meta‐analysis included seven studies with 3266 patients and found no significant difference between tenecteplase and standard medical care in terms of the mRS score at 90 days (mean difference = −0.16, p = 0.58), functional independence (mRS 0–2 at 90 days) (odds ratio = 1.07, p = 0.51), and reperfusion (TICI 2b‐3 at 24 h) (odds ratio = 1.33, p = 0.39). However, tenecteplase was associated with significantly higher mRS 0–1 at 90 days (odds ratio = 1.22, p = 0.01), better recanalization at 24 h (odds ratio = 3.28, p = 0.04), and improved NIHSS scores at 7 days (mean difference = −0.71, p = 0.003). On the downside, tenecteplase showed a significantly higher incidence of symptomatic intracranial hemorrhage (SICH) within 36 h (odds ratio = 2.24, p = 0.04) and any ICH (odds ratio = 1.40, p = 0.04), with no significant differences in mortality at 90 days (odds ratio = 1.18, p = 0.33) or stroke recurrence (odds ratio = 1.23, p = 0.55) and Barthel Index Score (odds ratio = 1.09, p = 0.69) and quality of life. Serious adverse events were slightly higher in the tenecteplase group but did not reach statistical significance (odds ratio = 1.18, p = 0.23). Conclusion: Tenecteplase improves early neurological recovery and recanalization and provides excellent functional outcomes in acute ischemic stroke. However, it is associated with a higher risk of symptomatic and overall intracranial hemorrhage. Mortality, stroke recurrence, and overall functional independence remain unaffected.
- 1 September 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (9) , e70791
Open AccessEfficacy and Safety of Tenecteplase in Acute Ischemic Stroke: A Meta‐Analysis of Randomized Controlled Trials
Introduction: Acute ischemic stroke (AIS) is the most common type of stroke, with increasing incidence and significant healthcare costs. Tenecteplase (TNK), a modified variant of tissue plasminogen activator (tPA), offers advantages such as a longer half‐life and single‐bolus administration. This meta‐analysis evaluates the safety and efficacy of TNK compared to non‐thrombolytic management in AIS to guide clinical decision‐making. Methodology: A comprehensive literature search across major databases identified randomized controlled trials (RCTs) comparing tenecteplase with non‐thrombolytic care in ischemic stroke. Data extraction and bias assessment were conducted independently, using RoB 2.0 and the GRADE framework. Meta‐analysis was performed using RevMan 5.4.1, applying random‐effects models and assessing heterogeneity with the I 2 statistic. Results: This meta‐analysis included seven studies with 3266 patients and found no significant difference between tenecteplase and standard medical care in terms of the mRS score at 90 days (mean difference = −0.16, p = 0.58), functional independence (mRS 0–2 at 90 days) (odds ratio = 1.07, p = 0.51), and reperfusion (TICI 2b‐3 at 24 h) (odds ratio = 1.33, p = 0.39). However, tenecteplase was associated with significantly higher mRS 0–1 at 90 days (odds ratio = 1.22, p = 0.01), better recanalization at 24 h (odds ratio = 3.28, p = 0.04), and improved NIHSS scores at 7 days (mean difference = −0.71, p = 0.003). On the downside, tenecteplase showed a significantly higher incidence of symptomatic intracranial hemorrhage (SICH) within 36 h (odds ratio = 2.24, p = 0.04) and any ICH (odds ratio = 1.40, p = 0.04), with no significant differences in mortality at 90 days (odds ratio = 1.18, p = 0.33) or stroke recurrence (odds ratio = 1.23, p = 0.55) and Barthel Index Score (odds ratio = 1.09, p = 0.69) and quality of life. Serious adverse events were slightly higher in the tenecteplase group but did not reach statistical significance (odds ratio = 1.18, p = 0.23). Conclusion: Tenecteplase improves early neurological recovery and recanalization and provides excellent functional outcomes in acute ischemic stroke. However, it is associated with a higher risk of symptomatic and overall intracranial hemorrhage. Mortality, stroke recurrence, and overall functional independence remain unaffected.
- Open Access
- 22 August 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (5) , e70091
Mortality Trends and Disparities in Cerebrovascular Disease Among Diabetic Population in the United States From 1999 to 2020: A CDC WONDER Analysis
Background: Diabetes mellitus (DM) significantly increases the risk of cerebrovascular disease (CeVD), a major cause of mortality and long‐term disability. Despite improvements in healthcare, disparities in CeVD‐related mortality among diabetic populations in the United States persist. Methods: We conducted a retrospective analysis using the CDC WONDER database from 1999 to 2020 to assess mortality trends related to CeVD among adults aged ≥ 45 years with DM. Deaths were identified using ICD‐10 codes I60–I69 (CeVD) and E10–E14 (DM). Age‐adjusted mortality rates (AAMRs) were calculated, and trends were analysed using Joinpoint regression, stratified by age, race/ethnicity, geography, urbanisation, and place of death. Results: A total of 689,846 CeVD‐related deaths occurred in diabetic individuals. AAMR decreased from 36.9 in 1999 to 29.3 in 2020, with an average annual percentage change (AAPC) of −1.41%. However, a sharp rise was observed from 2018 to 2020 (APC 14.87%), indicating a concerning reversal in progress. The highest crude mortality rates were in the 75–84 age group, and the lowest in the 45–54 group. Black and Hispanic populations, rural residents, and those in the Southern United States had the highest mortality rates. The Northeast and Asian populations had the lowest, reflecting persistent disparities in access to care and preventive services. Conclusion: While CeVD mortality in diabetics declined over two decades, the recent reversal highlights emerging challenges, possibly due to healthcare disruptions and socioeconomic disparities. These findings underscore the need for targeted public health interventions to address inequities and improve outcomes in high‐risk populations.
- 22 August 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (5) , e70091
Open AccessMortality Trends and Disparities in Cerebrovascular Disease Among Diabetic Population in the United States From 1999 to 2020: A CDC WONDER Analysis
Background: Diabetes mellitus (DM) significantly increases the risk of cerebrovascular disease (CeVD), a major cause of mortality and long‐term disability. Despite improvements in healthcare, disparities in CeVD‐related mortality among diabetic populations in the United States persist. Methods: We conducted a retrospective analysis using the CDC WONDER database from 1999 to 2020 to assess mortality trends related to CeVD among adults aged ≥ 45 years with DM. Deaths were identified using ICD‐10 codes I60–I69 (CeVD) and E10–E14 (DM). Age‐adjusted mortality rates (AAMRs) were calculated, and trends were analysed using Joinpoint regression, stratified by age, race/ethnicity, geography, urbanisation, and place of death. Results: A total of 689,846 CeVD‐related deaths occurred in diabetic individuals. AAMR decreased from 36.9 in 1999 to 29.3 in 2020, with an average annual percentage change (AAPC) of −1.41%. However, a sharp rise was observed from 2018 to 2020 (APC 14.87%), indicating a concerning reversal in progress. The highest crude mortality rates were in the 75–84 age group, and the lowest in the 45–54 group. Black and Hispanic populations, rural residents, and those in the Southern United States had the highest mortality rates. The Northeast and Asian populations had the lowest, reflecting persistent disparities in access to care and preventive services. Conclusion: While CeVD mortality in diabetics declined over two decades, the recent reversal highlights emerging challenges, possibly due to healthcare disruptions and socioeconomic disparities. These findings underscore the need for targeted public health interventions to address inequities and improve outcomes in high‐risk populations.
- 23 July 2025
- Published by SAGE Publications in Asia Pacific Journal of Public Health
- Vol. 37 (8) , 738-739
Comment on “Association Between Systemic Health Indicators and Periodontal Disease in Korean Adults: A Nationwide Cross-Sectional Study”
- 23 July 2025
- Published by SAGE Publications in Asia Pacific Journal of Public Health
- Vol. 37 (8) , 738-739
Comment on “Association Between Systemic Health Indicators and Periodontal Disease in Korean Adults: A Nationwide Cross-Sectional Study”